Last reviewed · How we verify
GC Fuji IX, GC, Japan®
GC Fuji IX, marketed by Liaquat University of Medical & Health Sciences, is a dental restorative material with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use in dental applications. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | GC Fuji IX, GC, Japan® |
|---|---|
| Sponsor | Liaquat University of Medical & Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Evaluation of Bioactive Resin Composites Versus Caries Control Technique in Management of Class I Carious Cavities in High Caries Risk Patients: a Randomized Clinical Trial (NA)
- Postoperative Sensitivity Following Placement with Different Restorative Materials in Vital Posterior Teeth (PHASE4)
- Comparison of Silver Modified and Conventional Atraumatic Restorative Treatment Modalities (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC Fuji IX, GC, Japan® CI brief — competitive landscape report
- GC Fuji IX, GC, Japan® updates RSS · CI watch RSS
- Liaquat University of Medical & Health Sciences portfolio CI